



## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>5</sup> :</b>  <b>A61K 7/48, 37/547</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/19732</b>  <b>(43) International Publication Date:</b> 14 October 1993 (14.10.93)
<b>(21) International Application Number:</b> PCT/GB93/00666 <b>(22) International Filing Date:</b> 31 March 1993 (31.03.93)  <b>(30) Priority data:</b> 9207288.3                      2 April 1992 (02.04.92)                      GB  <b>(71) Applicant (for AU CA GB IE only):</b> UNILEVER PLC [GB/GB]; Unilever House, Blackfriars, London EC4P 4BQ (GB).  <b>(71) Applicant (for all designated States except AU CA GB IE):</b> UNILEVER NV [NL/NL]; Weena 455, NL-3013 AL Rotterdam (NL).  <b>(72) Inventors:</b> RAWLINGS, Anthony, Vincent ; 509 Spencer Drive, Wyckoff, NJ 07481 (US). WATKINSON, Allan ; 20 Hunts Path, Oakley, Bedford MK43 7SR (GB).		<b>(74) Agent:</b> TONGE, R., J.; Patent Division, Unilever plc, Colworth House, Sharnbrook, Bedford MK44 1LQ (GB).  <b>(81) Designated States:</b> AU, BR, CA, JP, KR, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).  <b>Published</b> <i>With international search report.</i>
<b>(54) Title:</b> SKIN CARE METHOD AND COMPOSITION  <b>(57) Abstract</b>  A composition for topical application to the skin for alleviation or prevention of dry flaky skin condition, dandruff or acne comprising stratum corneum chymotrypsin-like enzyme. The composition may additionally comprise a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LI	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

- 1 -

SKIN CARE METHOD AND COMPOSITIONFIELD OF THE INVENTION

5           The invention relates to alleviation or prevention of dry flaky skin conditions by the topical application of stratum corneum chymotrypsin-like enzyme within a skin care composition. This composition may also be used to alleviate acne or dandruff.

10

BACKGROUND TO THE INVENTION AND PRIOR ART

15           In normal, healthy epidermis the continuous production of new stratum corneum is balanced by a well-regulated shedding of corneocytes from the skin surface. Little is known about this desquamation process at the molecular level.

20           It has been shown by A. Lundström and T. Egelrud (J. Invest Dermatol, (1988) 91 340-343; Arch Dermatol Res (1990) 282 234-237; J. Invest Dermatol (1990) 94 216-220) that cohesion between cells in the stratum corneum is dependant on protein structures. These structures must be degraded before cell dissociation can occur.

25

          Furthermore, evidence has been provided to show that cell dissociation is preceded by a degradation of the extracellular parts of desmosomes. (T. Egelrud (1992) European Journal of Dermatology 2 46-49).

- 2 -

5 A. Lundström and T. Egelrud have shown that the stratum corneum contains a protease enzyme - stratum corneum chymotrypsin-like enzyme (SCCE) which may be involved in the process of cell dissociation (desquamation): (Acta Derm Venereol (1991) 71 471-474), and that this enzyme may be involved in desmosomal degradation.

10 There has been much activity by cosmetic companies to solve the problem of being able to provide a skin care composition which is truly effective against dry flaky skin conditions. However until now no solution to this problem has been found.

15 We have surprisingly discovered that desmosomal structures are present in the uppermost layers of the stratum corneum in dry flaky skin conditions, this is not the case in normal skin. Furthermore, we have been able to substantially solve the problem of dry flaky skin  
20 conditions by topical application of a skin care composition comprising stratum corneum chymotrypsin-like enzyme.

#### DEFINITION OF THE INVENTION

25 Accordingly the invention provides a composition for topical application to the skin, which alleviates or prevents dry skin conditions comprising stratum corneum chymotrypsin-like enzyme.

30 Preferably the composition comprises 0.00001 to 50% more preferably 0.001 to 20% and even more preferably 0.1 to 10% by weight of the composition stratum corneum chymotrypsin-like enzyme.

- 3 -

Compositions may also additionally include a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof. Preferably the composition comprises 0.00001 to 50%, more preferably 0.001 to 20%, even more preferably 0.1 to 10% by weight of the composition of the second enzyme.

When such compositions of the invention comprise:

- (a) stratum corneum chymotrypsin-like enzyme; and
- (b) a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof;

the ratio of (a) to (b) is preferably 100:1 to 1:1.

Preferably the second enzyme is a glycosidase.

Without wishing to be bound by theory. We believe that the skin care composition containing SCCE is functioning via the penetration of the topically applied SCCE into the uppermost layers of the stratum corneum, where it then assists in the degradation of the desmosomes abnormally present, thus allowing the cohesive links between the cells to break down and desquamation to occur. The activity of the stratum corneum chymotrypsin-like enzyme may be enhanced by the addition of glycosidases, other proteases, lipases or a mixture thereof to the composition.

#### Stratum Corneum Chymotrypsin-like Enzyme

Stratum corneum chymotrypsin-like enzyme may be extracted from human or animal skin or callus by high salt solution (eg. 2M NaCl), detergent or solvent extraction, and purified by chromatography or electrophoretic techniques. Recombinant stratum corneum chymotrypsin-like

enzyme may also be produced by biotechnological means by the over-expression of its gene in yeast, bacteria, plant or mammalian cells.

5 Glycosidases

Glycosidases may be isolated from animal, plant, fungal or bacterial sources. Typical enzymes include neuraminidase, mannosidase, galactosidase, glucosidase, N-acetyl glucosaminidase and N-acetyl galactosaminidase. Preferably these may be isolated from plant sources including almonds, green coffee beans, and spinach, or may be obtained commercially.

15 Other Proteases

Other proteases may be isolated from animal, plant, fungal or bacterial sources. Suitable enzymes include bromelain, papain, chymotrypsin & chymotrypsin-like enzymes, cathepsin and cathepsin-like enzymes, alcalase, savinase, chymopapain, clostripain, endoproteinase Asp N, protease V.8, proteinase K, subtilisin, thermolysin, plasmin, pronase, and trypsin & trypsin-like enzyme. Preferably the protease may be isolated from plant sources including the seeds of wheat, barley, maize, oilseed rape, cocoa, linseed, illipe, shea nut, palm kernal, jojoba bean, pea, green bean, broad bean, soya bean and sunflower, and olives, papaya, pineapple, coconut, tomato and figs.

30 Lipases

Lipases, or similar lipid modifying enzymes, may be isolated from plant, animal or bacterial sources. Suitable enzymes include lipolase, pancreatic lipases, phospholipases, ceramidase, aryl sulphatase, cholesterol esterase, candida rugosa OF360 lipase, humicola sp. lipase, pseudomonas sp. lipase and Candida antarctica A & B lipases.

The Vehicle

5 The composition according to the invention also comprises a vehicle to act as a dilutant, dispersant or carrier for the active ingredients in the composition, so as to facilitate their distribution when the composition is applied to the skin and/or hair. Preferably the vehicle is cosmetically acceptable.

10 Vehicles other than water can include liquid or solid emollients, solvents, humectants, thickeners and powders. Examples of each of these types of vehicle, which can be used singly or as mixtures of one or more vehicles, are as follows:

15

Emollients, such as stearyl alcohol, glyceryl monoricinoleate, glyceryl monostearate, mink oil, cetyl alcohol, isopropyl isostearate, stearic acid, isobutyl palmitate, isocetyl stearate, oleyl alcohol, isopropyl laurate, hexyl laurate, decyl oleate, octadecan-2-ol, isocetyl alcohol, eicosanyl alcohol, behenyl alcohol, cetyl palmitate, silicone oils such as dimethylpolysiloxane, di-n-butyl sebacate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, butyl stearate, polyethylene glycol, triethylene glycol, lanolin, cocoa butter, corn oil, cotton seed oil, tallow, lard, olive oil, palm kernel oil, rapeseed oil, safflower seed oil, evening primrose oil, soybean oil, sunflower seed oil, avocado oil, olive oil, sesame seed oil, coconut oil, arachis oil, castor oil, acetylated lanolin alcohols, petroleum jelly, mineral oil, butyl myristate, isostearic acid, palmitic acid, isopropyl linoleate, lauryl lactate, myristyl lactate, decyl oleate, myristyl myristate;

20  
25  
30  
35

- 6 -

Propellants, such as air, propane, butane, isobutane, dimethyl ether, carbon dioxide, nitrous oxide;

5 Solvents, such as ethyl alcohol, methylene chloride, isopropanol, acetone, ethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoethyl ether, dimethyl sulphoxide, dimethyl formamide, tetrahydrofuran;

10 Powders, such as chalk, talc, fullers earth, kaolin, starch, gums, colloidal silica sodium polyacrylate, tetra alkyl and/or trialkyl aryl ammonium smectites, chemically modified magnesium aluminium silicate, organically modified montmorillonite clay, hydrated aluminium silicate, fumed  
15 silica, carboxyvinyl polymer, sodium carboxymethyl cellulose, ethylene glycol monostearate.

The vehicle will usually form from 10 to 99.9%, preferably from 50 to 99% by weight of the emulsion, and  
20 can, in the absence of other adjuncts, form the balance of the composition.

#### Optional Skin Benefit Materials And Cosmetic Adjuncts

25 A particularly convenient form of the composition according to the invention is an emulsion, in which case an oil or oily material will normally be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on  
30 the average hydrophilic-lyophilic balance (HLB) of the emulsifier employed.

#### Oil or Oily Material

35 The composition according to the invention can optionally comprise one or more oils or other materials having the properties of an oil.

- 7 -

Examples of suitable oils include mineral oil and vegetable oils, and oil materials, such as those already proposed herein as emollients. Other oils or oily materials include silicone oils, both volatile and non-volatile, such as polydimethyl siloxanes.

The oil or oily material, when present for the purposes for forming an emulsion, will normally form up to 90%, preferably from 10 to 80% by volume of the composition.

#### Emulsifier

The composition according to the invention can also optionally comprise one or more emulsifiers the choice of which will normally determine whether a water-in-oil or an oil-in-water emulsion is formed.

When a water-in-oil emulsion is required, the chosen emulsifier or emulsifiers should normally have an average HLB value of from 1 to 6. When an oil-in-water emulsion is required, a chosen emulsifier or emulsifiers should have an average HLB value of >6.

Examples of suitable emulsifiers are set out below in Table 1 in which the chemical name of the emulsifiers is given together with an example of a trade name as commercially available, and the average HLB value.

TABLE 1

	Chemical Name of Emulsifier	Trade Name	HLB Value
5	Sorbitan trioleate	Arlacel 85	1.8
	Sorbitan tristearate	Span 65	2.1
	Glycerol monooleate	Aldo MD	2.7
	Glycerol monostearate	Atmul 84S	2.8
10	Glycerol monolaurate	Aldo MC	3.3
	Sorbitan sesquioleate	Arlacel 83	3.7
	Sorbitan monooleate	Arlacel 80	4.3
	Sorbitan monostearate	Arlacel 60	4.7
	Polyoxyethylene (2) stearyl ether	Brij 72	4.9
15	Polyoxyethylene sorbitol beeswax derivative	G-1702	5
	PEG 200 dilaurate	Emerest 2622	6.3
	Sorbitan monopalmitate	Arlacel 40	6.7
20	Polyoxyethylene (3.5) nonyl phenol	Emulgen 903	7.8
	PEG 200 monostearate	Tegester PEG 200 MS	8.5
	Sorbitan monolaurate	Arlacel 200	8.6
25	PEG 400 dioleate	Tegester PEG 400-DO	8.8
	Polyoxyethylene (5) monostearate	Ethofat 60-16	9.0
30	Polyoxyethylene (4) sorbitan monostearate	Tween 61	9.6
	Polyoxyethylene (4) lauryl ether	Brij 30	9.7
	Polyoxyethylene (5) sorbitan monooleate	Tween 81	10.0
35	PEG 300 monooleate	Neutronyx 834	10.4
	Polyoxyethylene (20) sorbitan tristearate	Tween 65	10.5

- 9 -

	Polyoxyethylene (20)		
	sorbitan trioleate	Tween 85	11.0
	Polyoxyethylene (8)		
	monostearate	Myrj 45	11.1
5	PEG 400 monooleate	Emerest 2646	11.7
	PEG 400 monostearate	Tegester PEG 400	11.9
	Polyoxyethylene 10		
	monooleate	Ethofat 0/20	12.2
	Polyoxyethylene (10)		
10	stearyl ether	Brij 76	12.4
	Polyoxyethylene (10)		
	cetyl ether	Brij 56	12.9
	Polyoxyethylene (9.3)		
	octyl phenol	Triton X-100	13.0
15	Polyoxyethylene (4)		
	sorbitan monolaurate	Tween 21	13.3
	PEG 600 monooleate	Emerest 2660	13.7
	PEG 1000 dilaurate	Kessco	13.9
	Polyoxyethylene sorbitol		
20	lanolin derivative	G-1441	14.0
	Polyoxyethylene (12)		
	lauryl ether	Ethosperse LA-12	14.4
	PEG 1500 dioleate	Pegosperse 1500	14.6
	Polyoxyethylene (14)		
25	laurate	Arosurf HFL-714	14.8
	Polyoxyethylene (20)		
	sorbitan monostearate	Tween	14.9
	Polyoxyethylene 20 sorbitan		
	monooleate	Tween 80	15.0
30	Polyoxyethylene (20)		
	stearyl ether	Brij 78	15.3
	Polyoxyethylene (20)		
	sorbitan monopalmitate	Tween 40	15.6
35	Polyoxyethylene (20) cetyl		
	ether	Brij 58	15.7

- 10 -

	Polyoxyethylene (25)		
	oxypropylene	G-2162	16.0
	monostearate		
	Polyoxyethylene (20)		
5	sorbitol monolaurate	Tween 20	16.7
	Polyoxyethylene (23)		
	lauryl ether	Brij 35	16.9
	Polyoxyethylene (50)		
	monostearate	Myrj 53	17.9
10	PEG 4000 monostearate	Pegospense 4000	
		MS	18.7

-----

The foregoing list of emulsifiers is not intended to be limiting and merely exemplifies selected emulsifiers which are suitable for use in accordance with the invention.

It is to be understood that two or more emulsifiers can be employed if desired.

The amount of emulsifier or mixtures thereof, to be incorporated in the composition of the invention, when appropriate is from 1 to 50%, preferably from 2 to 20% and most preferably from 2 to 10% by weight of the composition.

#### Water


The composition of the invention can also comprise water, usually up to 80%, preferably from 5 to 80% by volume.

#### Silicone Surfactant


The composition of the invention can also optionally comprise a high molecular weight silicone surfactant which can also act as an emulsifier, in place of or in addition to the optional emulsifier(s) already mentioned.

- 11 -

The silicone surfactant is a high molecular weight polymer of dimethyl polysiloxane with polyoxyethylene and/or polyoxypropylene side chains having a molecular weight of from 10,000 to 50,000 and having the structure:



where the groups R' and R'' are each chosen from -H, C<sub>1-18</sub> alkyl and



a has a value of from 9 to 115,

20 b has a value of from 0 to 50,

x has a value of from 133 to 673,

y has a value of from 25 to 0.25.

25 Preferably, the dimethyl polysiloxane polymer is one in which:

a has a value of from 10 to 114

b has a value of from 0 to 49

x has a value of from 388 to 402

30 y has a value of from 15 to 0.75

one of groups R' and R'' being lauryl, and the other having a molecular weight of from 1000 to 5000.

35 A particularly preferred dimethyl polysiloxane polymer is one in which:

- 12 -

a has the value 14  
b has the value 13  
x has the value 249  
y has the value 1.25

5

The dimethyl polysiloxane polymer is conveniently provided as a dispersion in a volatile siloxane, the dispersion comprising, for example, from 1 to 20% by volume of the polymer and from 80 to 99% by volume of the volatile siloxane. Ideally, the dispersion consists of a 10% by volume of the polymer dispersed in the volatile siloxane.

10

15

Examples of the volatile siloxanes in which the polysiloxane polymer can be dispersed include polydimethyl siloxane (pentamer and/or hexamer).

20

A particularly preferred silicone surfactant is cyclomethicone and dimethicone copolyol, such as DC 3225C Formulation Aid available from DOW CORNING. Another is laurylmethicone copolyol, such as DC Q2-5200, also available from Dow Corning.

25

The amount of silicone surfactant, when present in the composition will normally be up to 25%, preferably from 0.5 to 15% by weight of the emulsion.

#### Other Adjuncts

30

35

Examples of conventional adjuncts which can optionally be employed include preservatives, such as para-hydroxy benzoate esters; antioxidants, such butyl hydroxy toluene; humectants, such as glycerol, sorbitol, 2-pyrrolidone-5-carboxylate, dibutylphthalate, gelatin, polyethylene glycol, preferably PEG 200-600; buffers, such as lactic acid together with a base such as triethanolamine or sodium hydroxide; surfactants, such as glycerol ethers, ceramides of synthetic, animal or plant origin; waxes, such as

beeswax, ozokerite wax, paraffin wax; plant extracts, such as Aloe vera, cornflower, witch hazel, elderflower, cucumber; thickeners; activity enhancers; colourants; perfumes; and sunscreen materials such as ultrafine titanium dioxide and organic sunscreens such as p-aminobenzoic acid and esters thereof, ethylhexyl p-methoxycinnamate, 2-ethoxyethyl p-methoxycinnamate and butyl methoxydibenzoylmethane, and mixtures thereof.

Since stratum corneum chymotrypsin enzyme is inhibited by zinc ions, metal chelators such as EDTA may be optionally included in the composition to increase activity/decrease inhibition.

#### USE OF THE COMPOSITION

The composition according to the invention is intended primarily as a product for topical application to human skin, for treating dry flaky skin and to enhance the quality of skin. The composition may also be used to alleviate acne and dandruff.

In use, a small quantity of the composition, for example from 1 to 5ml, is applied to areas of the skin or hair, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin or scalp using the hand or fingers or a suitable device.

#### PRODUCT FORM AND PACKAGING

The topical skin and/or hair treatment composition of the invention can be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas, or above. The composition can be packaged in a suitable

- 14 -

container to suit its viscosity and intended use by the consumer. For example, a lotion or fluid cream can be packaged in a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a non-deformable bottle or squeeze container, such as a tube or a lidded jar. The composition may be used for general lotions and creams, leave-on-creams, wash-off cleansers, face masks shampoos and bath oils.

The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.

15

#### EXAMPLES

##### In Vitro Assay To Screen For Desmosome Digestion Activity

Stratum corneum cells with desmosomes still attached were obtained by tape stripping human or animal skin. To release the cells from the tape the whole tape was placed into hexane and the cells were collected by centrifugation after which the hexane was aspirated. Alternatively, human plantar stratum corneum, a tissue rich in desmosomes, was ground in liquid nitrogen and dried. The cells were then dispersed into buffer containing a high salt stratum corneum chymotrypsin enzyme extract from pig stratum corneum, in the presence or absence of specific inhibitors to verify enzyme activity. To ascertain the effect of glycosidases, some corneocyte aliquots were treated with a mixture of almond meal extract and neuramidase prior to incubation with the SCCE extract.

Desmosome digestion can then be followed microscopically by examining cell dissociation using an optical microscope. When enzymes fail to digest the

- 15 -

desmosomes the cells remain attached to each other. Thus, counting the number of dispersed cells or measuring the dispersed cell mass using a protein assay can be used as a measure of enzyme efficiency. To ensure enzymes were specifically degrading desmosomes, the specific desmosomal digestion by the enzyme was demonstrated as follows:

The desmosomal protein, desmoglein, (dg1) was isolated from the squames by extraction in a urea/SDS/ $\beta$ -mercaptoethanol buffer with subsequent purification of the dg1 glycoprotein using concavalin A affinity chromatography. The concavalin A eluate was fractionated by sodium dodecyl sulphate polyacrylamide gel electrophoresis and electrophoretically transferred to PDVF membrane for immunoblotting. The dg1 was identified using a specific antiserum with low levels of the antigen being indicative of desmosomal digestion. Results obtained using this methodology are shown in Table 1.

This methodology allows the screening of enzymes prior to testing the most efficacious enzymes in vivo on human skin.

Table 1

Treatment	dg1 Levels
Control	100%
SCCE extract	13.9%
SCCE extract + 100 $\mu$ M Chymostatin	51.8%
SCCE extract + 1mM ZnSO <sub>4</sub>	74.6%
SCCE extract + 10 $\mu$ M Aprotinin	101.7%
Glycosidase pretreatment + SCCE extract	10.1%

35

- 16 -

The following examples are to illustrate compositions for topical application embodying the present invention.

A Typical Oil-In-Water Cream

5		<u>% w/w</u>
	SCCE	0.5
	Glycosidases	0.5
	Mineral oil	4.0
	Cetyl alcohol POE	4.0
10	Cetyl alcohol	4.0
	Triethanolamine	0.75
	Butane 1, 3 diol	3.0
	Xanthum gum	0.3
	Preservative	0.4
15	Perfume	qs
	Butylated hydroxytoluene	0.01
	Water	to 100

A Typical Lotion

20		<u>% w/w</u>
	SCCE	1.0
	Ethanol	10.0
	Perfume	qs
	Butylated hydroxytoluene	0.01
25	Water	to 100

Water In Oil Emulsion

		<u>% w/w</u>
30	Fully hydrogenated coconut oil	3.9
	SCCE	0.5
	Glycosidase	0.5
	Polyoxyethylene oleyl ether	5.0
	Bentone 38	0.5
	Preservative	0.3
35	MgSO <sub>4</sub> 7H <sub>2</sub> O	0.3
	Butylated hydroxytoluene	0.01
	Perfume	qs
	Water	to 100

CLAIMS

- 5 1. A composition for topical application to the skin which alleviates or prevents dry flaky skin conditions comprising stratum corneum chymotrypsin-like enzyme
- 10 2. A composition according to claim 1 wherein the composition comprises 0.00001 to 50% by weight of the composition stratum corneum chymotrypsin-like enzyme.
- 15 3. A composition according to claim 1 or 2 wherein the composition comprises 0.001 to 20% by weight of the composition stratum corneum chymotrypsin-like enzyme.
- 20 4. A composition according to any preceding claim wherein the composition comprises 0.1 to 10% by weight of the composition stratum corneum chymotrypsin-like enzyme.
- 25 5. A composition according to any preceding claim wherein the composition additionally comprises a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof.
- 30 6. A composition according to claim 5 wherein the composition comprises 0.00001 to 50% by weight of the composition of the second enzyme.
- 35 7. A composition according to claim 5 or claim 6 wherein the composition comprises 0.001 to 20% by weight of the composition of the second enzyme.
8. A composition according to claims 5, 6 or 7 wherein the composition comprises 0.1 to 10% by weight of the composition of the second enzyme.
9. A composition according to any preceding claim wherein the composition comprises:

- 18 -

- (a) stratum corneum chymotrypsin-like enzyme; and
- (b) a second enzyme selected from glycosidases, other proteases, lipases and mixtures thereof;

5 wherein the ratio of (a) to (b) is 100:1 to 1:1.

10. A composition according to any one of claims 5 to 9 wherein the second enzyme (b) is a glycosidase.

10 11. A composition according to any one of the preceding claims wherein the composition further comprises a cosmetically acceptable vehicle for the enzyme.

15 12. The use of a composition according to any of the preceding claims for topical application to dry skin conditions, acne and dandruff.

20 13. A method of relieving or ameliorating dry skin conditions, acne and dandruff which includes the topical application to the skin of a composition comprising stratum corneum chymotrypsin-like enzyme.

## INTERNATIONAL SEARCH REPORT

PCT/GB 93/00666

International Application No

<b>I. CLASSIFICATION OF SUBJECT MATTER</b> (if several classification symbols apply, indicate all) <sup>6</sup>		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5 A61K7/48;                      A61K37/547		
<b>II. FIELDS SEARCHED</b>		
Minimum Documentation Searched <sup>7</sup>		
Classification System	Classification Symbols	
Int.Cl. 5	A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched <sup>8</sup>		
<b>III. DOCUMENTS CONSIDERED TO BE RELEVANT<sup>9</sup></b>		
Category <sup>10</sup>	Citation of Document, <sup>11</sup> with indication, where appropriate, of the relevant passages <sup>12</sup>	Relevant to Claim No. <sup>13</sup>
A	ACTA. DERM. VENEREOL. vol. 71, no. 6, 1991, STOCKHOLM, SE pages 471 - 474 LUNDSTRÖM ET AL. 'STRATUM CORNEUM CHYMOTRYPTIC ENZYME' cited in the application see the whole document ---	1-4
A	FR,A,1 579 878 (SPOFA) 29 August 1969 see the whole document ---	1-13
A	FR,A,2 556 218 (GERARD ET AL.) 14 June 1985 see the whole document ---	1-13
A	US,A,3 660 566 (VINSON ET AL.) 2 May 1972 see the whole document -----	1-4
<p><sup>10</sup> Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&amp;" document member of the same patent family</p>		
<b>IV. CERTIFICATION</b>		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
13 JULY 1993	١٣ جويلية ١٩٩٣	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	FISCHER J.P.	

**ANNEX TO THE INTERNATIONAL SEARCH REPORT  
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 9300666  
SA 72198

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 13/07/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
FR-A-1579878	29-08-69	BE-A- 720609	17-02-69
		CH-A- 547095	29-03-74
		DE-A- 1792508	20-04-72
FR-A-2556218	14-06-85	None	
US-A-3660566	02-05-72	None	